TP508 — EU research guide.

TP508 (Chrysalin, rusalatide acetate) is a 23-amino-acid fragment of human thrombin studied for accelerating wound, bone and vascular repair — in the same tissue-regeneration territory as BPC-157 and TB-500.

Last reviewed: 2026-07-04

What is TP508?

TP508 reproduces thrombin's receptor-binding domain without its clotting activity, activating repair pathways on endothelial cells, fibroblasts and osteoblasts. Preclinical work shows it promotes angiogenesis, reverses endothelial dysfunction and speeds fracture and wound healing.

What does the research show?

Human trials by OrthoLogic/Chrysalis BioTherapeutics demonstrated accelerated healing of diabetic foot ulcers and distal radius fractures with local administration, with no drug-related adverse events reported. More recent preclinical work has explored systemic TP508 for radiation injury and ARDS, but no product has reached full regulatory approval.

EU legal status

Not an approved medicine anywhere; sold by RUO peptide suppliers as a research chemical only, with batch-specific COAs available from specialised vendors.

⚠ Investigational compound; human trials used local, site-of-injury administration rather than systemic injection. Not evaluated for general self-administered use.

✓ For the more widely available regenerative research peptides, PeptideCompare tracks BPC-157 and TB-500 from EU research vendors with COA documentation.

Molecular information

Molecular formula

C97H146N28O36S

Molecular weight

2312.44 g/mol

CAS number

121341-81-9

Pharmacokinetics

No established human pharmacokinetic data. Published human PK parameters for this compound are not available; reported data are limited to animal models or absent. No curve is shown, to avoid implying data that does not exist.

Tissue-repair compounds across EU suppliers

COA-verified EU vendors · Updated monthly